SCHEMBL6049486

SCHEMBL6049486

Nc1nc(N)c(-c2cccc(Cl)c2Cl)c(CO)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.50
ADRA1A P35348 2/20 0.50
MAOA P21397 1/20 0.50
MAPK1 P28482 1/20 0.50
SCN4A P35499 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
PDE3A Q14432 1/20 0.50
SCN5A Q14524 1/20 0.50
SCN9A Q15858 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50
SCN10A Q9Y5Y9 1/20 0.50
HEXA P06865 3/20 0.44
HEXB P07686 3/20 0.44
NUDT1 P36639 4/20 0.43
PTPN11 Q06124 6/20 0.42
DHFR P00374 3/20 0.42
MEN1 O00255 1/20 0.42
SLC22A1 O15245 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310324 0.85 CYP2D6 (0.50) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL6049489 0.85 HEXA (0.62) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL29384947 0.85 CYP2D6 (0.50) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL5072676 0.85 CYP2D6 (0.47) CYP2D6ADRA1AMAOAMAPK1SCN4A
Hydrochloric Acid SCHEMBL7767228 0.84 CYP2D6 (0.49) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL5566857 0.83 CYP2D6 (0.48) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL5069251 0.82 HEXA (0.48) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL6049518 0.81 SCN2A (0.43) CYP2D6ADRA1ASCN5ASCN9ASCN2A
SCHEMBL6049459 0.80 CYP2D6 (0.54) CYP2D6ADRA1AMAOAMAPK1SCN4A
SCHEMBL6049519 0.80 CYP1A2 (0.57) CYP2D6ADRA1AMAOAMAPK1SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0879230-B1 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LTD (GB) 2001-07-25 EP claimed
US-6124308-A ANALGESICS, ANTICONVULSANTS, TREATING IRRITABLE BOWEL SYNDROME OR BIPOLAR DISORDER GLAXO WELLCOME INC. (US) 2000-09-26 US claimed
EP-0879230-A2 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LIMITED (GB) 1998-11-25 EP claimed
WO-1997009317-A2 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LIMITED (GB) 1997-03-13 WO claimed
US-5597828-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY GLAXO WELLCOME INC. (US) 1997-01-28 US claimed
EP-1681058-A2 Pharmacologically active cns compounds THE WELLCOME FOUNDATION LIMITED (GB) 2006-07-19 EP disclosed
EP-1325916-A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system THE WELLCOME FOUNDATION LIMITED (GB) 2003-07-09 EP disclosed
EP-0715851-B1 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders WELLCOME FOUND (GB) 2003-04-02 EP disclosed
US-6479498-B1 COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS THERAVANCE, INC. 2002-11-12 US disclosed
US-6420354-B1 Sodium channel drugs and uses ADVANCED MEDICINE, INC. 2002-07-16 US disclosed
WO-1999063984-A9 NOVEL SODIUM CHANNEL DRUGS AND USES 2002-04-25 WO disclosed
EP-0879230-B1 OPTICALLY ACTIVE PHENYL PYRIMIDINE DERIVATIVE AS ANALGESIC AGENT GLAXO GROUP LTD (GB) 2001-07-25 EP disclosed
EP-0727213-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727214-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727212-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0715851-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-06-12 EP disclosed
EP-0713703-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-05-29 EP disclosed
CN-1117046-A Method for preparing pharmaceutically active CNS compounds WELLCOME FOUND (GB) 1996-02-21 CN disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed